KLP Kapitalforvaltning AS Acquires Shares of 26,200 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

KLP Kapitalforvaltning AS acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 26,200 shares of the biopharmaceutical company's stock, valued at approximately $1,253,000.

A number of other large investors have also recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in shares of Halozyme Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company's stock valued at $175,194,000 after buying an additional 30,901 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock valued at $85,254,000 after buying an additional 9,780 shares during the period. Boston Trust Walden Corp grew its position in Halozyme Therapeutics by 28.0% in the fourth quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company's stock worth $41,790,000 after acquiring an additional 191,465 shares during the period. American Century Companies Inc. lifted its stake in shares of Halozyme Therapeutics by 1.8% in the 4th quarter. American Century Companies Inc. now owns 866,366 shares of the biopharmaceutical company's stock valued at $41,421,000 after purchasing an additional 15,079 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Halozyme Therapeutics by 60.0% during the 4th quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company's stock worth $31,112,000 after purchasing an additional 243,940 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Halozyme Therapeutics Stock Down 1.7 %

Shares of HALO stock traded down $1.10 on Thursday, reaching $61.92. 1,883,135 shares of the stock were exchanged, compared to its average volume of 1,387,932. The company has a market capitalization of $7.65 billion, a price-to-earnings ratio of 18.05, a PEG ratio of 0.42 and a beta of 1.32. The business's 50 day moving average price is $59.74 and its 200 day moving average price is $54.95. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Finally, Benchmark reiterated a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $62.78.

Insider Activity

In other news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,200 shares of company stock worth $1,786,668. Corporate insiders own 2.90% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.